Fetal stem cell transplantation and gene therapy.

A-thalassemia Fetal therapy Gene therapy Hematopoetic stem cell Mesenchymal stem cells Osteogenesis imperfecta

Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 01 11 2018
accepted: 26 02 2019
pubmed: 27 3 2019
medline: 1 2 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

The present chapter summarizes our current knowledge on fetal stem cell and gene therapy. It focuses on these therapeutic alternatives in regard to past experiences and ongoing and planned studies in humans. Several methodological challenges are discussed that may have wide implications on how these methods could be introduced in clinical practices. Although still promising, the methods are afflicted with very special requirements not least in regard to safety and ethical questions. Furthermore, careful monitoring and extended follow-up of the child and his/hers mother who receive prenatal stem cell or gene treatments are of outmost importance. Taken these prerequisites into consideration, it is natural that this type of experimental fetal therapies requires collaboration between different disciplinaries and institutions within medicine.

Identifiants

pubmed: 30910447
pii: S1521-6934(18)30243-8
doi: 10.1016/j.bpobgyn.2019.02.007
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-153

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Rachel Sagar (R)

Institute for Women's Health, University College London, London, UK.

Cecilia Götherström (C)

Department of Clinical Science, Intervention and Technology, K57, Division of Obstetrics and Gynecology, Karolinska University Hospital, Huddinge Karolinska Institutet, Stockholm, Sweden.

Anna L David (AL)

Institute for Women's Health, University College London, London, UK; Katholieke Universiteit Leuven, Belgium.

Magnus Westgren (M)

Department of Clinical Science, Intervention and Technology, K57, Division of Obstetrics and Gynecology, Karolinska University Hospital, Huddinge Karolinska Institutet, Stockholm, Sweden. Electronic address: magnus.westgren@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH